



# Navigating the Regulatory Landscape and Orchestrating the Lifecycle Symphony of Medical Devices

Bhagyashree Chakole\*, Payal Madavi, Samir Bhoyar, Vinita Kale, Milind Umekar and Neha Raut

Department of Regulatory Affairs, Smt. Kishoritai Bhoyar College of Pharmacy, Kamptee, Nagpur 441002, Maharashtra, India. Institutional

(Received: 07 January 2024

Revised: 12 February 2024

Accepted: 06 March 2024)

## KEYWORDS

Medical devices, Good manufacturing practices, WHO, ISO, Clinical investigation, CDSCO, GHTF

## ABSTRACT:

In recent years, many diseases were diagnosed and managed using medical devices. It was crucial that these devices were safe and of high quality, adhering to the rules set by regulators. The purpose of this study was to provide an overview of the rules and regulations governing medical devices. These devices played a significant role in modern healthcare, directly influencing the quality of care received. While some devices notably improved care, others posed challenges. Ensuring these devices were top-notch relied heavily on adhering to established rules. Medical devices held substantial importance in healthcare, contributing to various aspects from aiding in diagnoses to being integral to treatments. To stay abreast of the latest developments, the healthcare sector needed continuous improvement. Good Manufacturing Practices served as a rulebook to guarantee that medical devices were of good quality, safe, and functioned effectively. When a new device was introduced, it underwent clinical investigations to ensure its safety and efficacy. Even after a device was released, its entire lifecycle was monitored, evaluated, and improved upon. Changes were occasionally made to a device after its approval, referred to as post-approval changes. This paper summarized the important rules and regulations necessary for managing medical devices, encompassing good manufacturing practices, clinical investigations, lifecycle management of the device, and changes made after approval.

**Conclusions:** Ensuring the safety and efficacy of medical devices was crucial for the well-being of patients, the optimal functioning of products, and compliance with evolving regulations. Essential measures included adherence to Good Manufacturing Practices (GMP), conducting robust clinical research, effective lifecycle management of the product, and meticulous handling of post-approval modifications. Staying vigilant in these areas was vital to navigate the dynamic landscape of medical device regulations and maintain a commitment to patient safety. These things were super important because they guaranteed that medical devices were safe and worked well in healthcare. The rules were getting stricter at every step, so companies needed to check and keep up their quality procedures. One big rulebook for managing quality in the medical devices industry was the ISO 13485:2016 standard. It was really important because it gave a full plan for managing quality, made just for the medical devices industry. It applied to all kinds of companies, big or small. The standard said that even if a company didn't do certain things,



but the standard said they should, it was still the company's job to take care of them. These things should have been part of the company's plan for managing quality, and they should have been watched, taken care of, and controlled. Taking this kind of approach, where a company was proactive about following rules and managing the life of the product well, not only helped with coming up with new ideas but also kept the medical device industry trustworthy. In the end, this helped both the companies making the devices and the patients who relied on these important technologies. Now, let's dive a bit deeper into why all this was so important. The rules and how a company managed a product's life were super important for the health of the public. When a company followed the rules and managed things well, it meant the devices they made were more likely to be safe and do their job well. This was crucial for patients who depended on these devices to stay healthy or get better. Think about it like this: if a company didn't follow the rules or didn't manage a device well, it could lead to problems. Maybe the device wouldn't work as it should, or it might even be unsafe for the person using it. This could have caused harm to the patient, and that was something everyone wanted to avoid. So, when companies followed the rules and managed things well, it was like a safety net for the people using the devices. It ensured that the devices were safe, effective, and did what they were supposed to do. This was especially important in healthcare, where people's well-being was at the center. Now, let's talk about the ISO 13485:2016 standard; it was like a guidebook that told companies how to manage quality, specifically for the medical devices they made. This standard didn't care if a company was big or small; it applied to all of them. It said that even if a company didn't do certain things, but the standard said they should, it was still their job to make sure those things were taken care of. This kind of proactive approach, where a company was on top of rules and managed a device well from the start to the end, was not just good for following the rules. It was also great for encouraging new and innovative ideas. When companies knew they were doing things the right way, it gave them the freedom to come up with new, better, and safer devices. This approach was like a win-win. It helped the companies because they could be more creative and successful, and it helped the patients because they could trust that the devices they used were safe and effective. Ultimately, all these rules and good management were about making sure that the medical device industry was solid, reliable, and focused on the well-being of the people it served.

## 1. Introduction

In the 1950s and 1960s, tremendous technological advances boosted innovation in the field of the pharmaceutical and medical device industry. Back then, these industries were evaluated to be worth billions of dollars. The quality of healthcare, such as the diagnosis, prevention, and treatment of diseases and serious health conditions, became easier and more efficient with the help of medical devices, which included everything from highly

complex computerized medical equipment to simple wooden tongue inhibitors [1]. The World Health Organization (WHO) defined a medical device as any tool, device, machine, equipment, implant, in vitro reagent, software, material, or any other item of a similar or related nature. Manufacturers designed it for use, either individually or in conjunction, for one or more specific medical objectives for humans [2]. According to Schedule M-III of the Drug and



Cosmetic Act 1940 and Rules 1945, a medical device was defined as a medical instrument that did not use pharmacological, immunological, or metabolic methods to primarily perform its function in or on the human body and was separate from drugs [3]. The Food and Drug Administration (FDA), the regulatory authority of the United States, also defined a medical device as a tool, device, machine, gadget, implant, in vitro reagent, or any other article that is similar or related. It was designed to be used in diagnosing diseases or other conditions, as well as in the healing, alleviation, management, or prevention of diseases [4]. A medical device was intended for use in diagnosis and treatment purposes to prevent and cure diseases, which could be any instrument, apparatus, appliance, software, material utilized individually or together. The Global Harmonization Task Force (GHTF), established in 1992, was created to ensure the safety, efficacy, and effectiveness of medical technologies and to enhance consistency across national medical device regulatory systems. The primary members of GHTF were Australia, Japan, Canada, EU, and the US. A medical device was defined by GHTF as any instrument, apparatus, implement, machine, appliance, implant, software material, or other article used for various purposes such as diagnosing, monitoring, or treating any type of disease or injury [5].

### Classification of Medical Devices

The GHTF grouped medical devices based on risk to assess the level of premarket regulatory control that was necessary, with the goal of ensuring that these controls were appropriate for each class to protect the health and safety of patients, users, and

**Table 1. Classification of Medical Devices as per CDSCO**

Class	Risk level	Examples	Brand name of medical device	Company
CLASS A	Low risk	Absorbent cotton, Surgical dressings	300 GM Absorbent Cotton Wool	Olivice Healthcare Private Limited
CLASS B	Low moderate risk	Thermometer, BP monitoring device	Dr Odin Led Digital Thermometer	D.P. Scientific Solutions
CLASS C	Moderate – high risk	Implants, hemodialysis catheter	Urinary Catheter	Angioplast Pvt. Ltd.
CLASS D	High risk	Heart valve, implantable defibrillator	Medical Heart Valves	Surgitech Healthcare Private Limited

other people [6]. The medical devices were divided into four classes on the basis of their risk level: A, B, C, and D as per Schedule M-III of D&C Act 1940 and rules 1945. The classification of medical devices was given in Table no. 1 as per Central Drugs Standard Control Organizations (CDSCO). The higher-risk medical devices required more regulations and a more stringent conformity assessment process. Physicians' ability to diagnose and treat diseases was greatly enhanced by medical devices, which significantly contributed to health and quality of life [7]. Regulatory authorities around the globe classified medical devices based on their safety, efficacy, and quality standards. This classification helped in setting appropriate standards worldwide. Medical device classification varied across different countries. In the past, medical devices were classified into different classes based on their risk levels, each subject to specific regulatory controls. Class A devices, which were deemed low-risk, were subjected to general controls to ensure their safety and efficacy. Class B devices, considered low-medium risk, were subject to a combination



of general control and specific controls tailored to their potential risks. Class C devices, identified as medium-high risk, necessitated certification by the notified body for both design and manufacturing aspects of medical devices. Class D devices, categorized as high-risk, mandated adherence to general controls and specific control measures, along with the requirement for premarket approval [8].

## 2.Life cycle of Medical Device Product

The life cycle of a medical device product was intertwined with the regulatory procedures followed by leaders in the industry in the EU, US, and various other nations that adopted similar policies. Although the legislative council and regulation connections were often not apparent to many, it was crucial for companies that manufactured and marketed these products to manage them throughout their lifecycle, as it directly impacted the end users. Recognizing the integral connection, the relationship among regulation, markets, and industries of medical devices was vital for producing safe as well as effective devices, fostering sustainable clinical advancements in the industry, and upholding everlasting medical ethics principles such as "do no harm." The life cycle of a medical product typically involved five stages, as mention in Fig. no. 1. regardless of whether the device was intended for diagnosis, treatment, or health education. These stages were research, production, testing, launch, and post-market evaluation [9].

**Research:** The initial concept could have been an innovative idea or an enhancement of an existing device. Regardless, comprehensive research was crucial to establish a feasible design. Many products did not advance beyond this stage due to inadequate research by their creators. Ideally, the following questions should have been addressed: Who was the intended user group? Which risks

were there associated with mechanical and manufacturing processes? and how did this concept stand out from other devices designed for the same function?

**Design:** The device underwent a process of creation, review, modification, and redesign using extreme programming engineering. Computer graphics and prototypes were utilized to evaluate the design and gauge its market potential. Some tools that fostered innovative thinking included Powder Layer Mergers, a technique that used a high-density laser to fuse powdered metal materials into 3D models and shapes. This method allowed designers to create more robust designs, making it a popular choice for prototyping medical devices. Additionally, Computer Numerical Control (CNC) Machining was a process that was particularly beneficial when manipulating unprocessed material to form a design. The modernization of manufacturing facilities and the use of 3D printers helped construct intricate, detailed designs, resulting in the production of high-quality prototypes. 3D printing democratized rapid prototyping, enabling manufacturers to create models faster and gain a more comprehensive understanding of them, providing the designer with a tangible concept that could be used to further refine the device.


**Validation:** The guidelines for specific medical devices were established by the FDA. These medical devices were classified as class I, class II, and class III based on their function, level of invasiveness, and risk. The class of the device determined the necessary controls for verifying the results and ensuring a successful outcome. Clinical trials were conducted and submitted at this stage, allowing the manufacturer to apply for premarket approval.

**Launch:** Once the content creator received the necessary pre-sale approval from the FDA, they could start promoting and selling their products.



Premarket approval was a communication from the FDA to content creators that signified the product was safe for public use. If a device required such approval, marketing or selling could not commence until it was received. Marketing had to collaborate closely with a legal team to ensure compliance with regulations and appropriateness of marketing strategies. Marketing messages and tactics had to be meticulously planned and were likely better managed by companies with specific expertise in medical devices.

**Post-market Review:** The project's journey didn't end with the device's public release. Post-launch, the creator was responsible for monitoring any adverse effects, conducting necessary inspections, reporting any negative incidents, and potentially managing recalls and device removals. Post-market surveillance played a crucial role in this phase as developers had to monitor the impact of their products and maintain detailed records, keeping track of medical history and patient registries was also vital. This phase might also involve introducing the device to secondary markets [10].



**Fig. no.1: Life Cycle of Medical Device Product**


### 3. Good Manufacturing Practice in Medical Devices

The proposal for Good Manufacturing Practice (GMP) regulations was first put forward in the United States in 1963, subsequent to the implementation of the Kefauver–Harris amendment on drug efficacy in 1962. These GMP regulations stipulated the necessary requirements for the production, packaging, and distribution of products intended for use by humans and animals. The objective of the GMP regulation and guidance statement was to fulfil one or more of the five attributes: safety, quality, purity, strength, and identity [11]. The Fig. no. 2 represents the GMP of medical devices which included design plan and development, risk management throughout the design process, prototyping, testing and refinement, verification and validation and detailed documentation. The GMP was designed to guarantee the safety of patients and users by implementing stringent quality control procedures. It mandated manufacturers to adhere to uniform production processes, thereby reducing the likelihood of flaws or operational issues that could potentially endanger patients or impair the performance of the device. GMP enhanced the efficacy of products; when devices complied with GMP standards, they were more likely to function as expected, providing precise and dependable results. This was especially important for diagnostic and therapeutic devices, as their accuracy had a direct effect on patient outcomes. GMP boosted both traceability and accountability; by keeping detailed records of manufacturing procedures, components used, and test outcomes, manufacturers could pinpoint the origin of any issues. This allowed for quick corrective measures and, if required, facilitated product recalls. Adherence to good manufacturing practice aided in the facilitation of international trade, given that similar regulations had been adopted by numerous countries. This compliance assisted manufacturers in fulfilling regulatory requirements across





various markets, thereby enhancing the global accessibility of safe and effective medical devices.[12].



**Fig. no. 2 : Good Manufacturing Practices of Medical Device**

The International Organization for Standardization (ISO) 13485 was a global standard outlining the criteria for a Quality Management System (QMS). The organization utilized QMS at any stage of the life cycle of medical devices. This included steps such as design and development, manufacturing, storage and distribution, installation, maintenance, and the final decommissioning and disposal of medical devices. It also covered the design and development or provision of related activities, such as technical support [13]. A QMS for medical devices was a structured system encompassing policies, processes, and procedures implemented by a medical device manufacturer. This system was designed to ensure the safety and effectiveness of their products for the purpose they were intended for [14]. ISO 13485:2016

requirements encompassed 8 clauses with supporting subclauses which are given in Table no. 2. The requirements to be applied to the QMS were covered in clauses 4-8 (12). As mentioned, Fig. no. 3 represents the QMS of medical devices.


**Table no. 2 : The ISO 13485:2016 represent QMS of medical devices**

<b>1.</b>	<b>Scope of the standard</b>
<b>2.</b>	Normative reference of the standard
<b>3.</b>	Terms and definitions of the standard
<b>4.</b>	Quality management system (QMS)
<b>4.1</b>	General requirements
<b>4.1.1</b>	Establish and maintain the effectiveness of the documented QMS
<b>4.1.2</b>	Document the responsibilities undertaken by the organization.
<b>4.1.3</b>	Develop a risk-based approach to manage the processes.
<b>4.1.4</b>	Validate the requirements for the application of computer software.
<b>4.2</b>	Documentation requirements
<b>4.2.1</b>	The quality manual
<b>4.2.2</b>	The medical device file
<b>4.2.3</b>	To have control of documents
<b>4.2.4</b>	To have control of record – confidential health information
<b>4.2.5</b>	Security of documents/records – prevention of loss
<b>5.</b>	Responsibility of management
<b>5.1</b>	Commitment of management
<b>5.2</b>	Customer focus
<b>5.3</b>	Quality policy
<b>5.4</b>	Planning
<b>5.5</b>	Responsibility, authority, and communication
<b>5.6</b>	Management review
<b>6.</b>	Management resource
<b>6.1</b>	Resource provisions



<b>6.2</b>	Human resources
<b>6.3</b>	Infrastructure
<b>6.4</b>	Work environment and contamination control
<b>6.4.1</b>	Work environment
<b>6.4.2</b>	Contamination control
<b>7.</b>	Product realization
<b>7.1</b>	Product realization planning
<b>7.2</b>	Processes related to customer
<b>7.2.1</b>	Determination of product-related requirements
<b>7.2.2</b>	Review of product requirements
<b>7.2.3</b>	Communication
<b>7.3</b>	Design and development
<b>7.3.1</b>	Design and development transfer
<b>7.3.2</b>	Design control and development changes
<b>7.3.3</b>	Design and development of files
<b>7.4</b>	Purchasing
<b>7.4.1</b>	Process of purchasing
<b>7.4.2</b>	Purchasing information
<b>7.4.3</b>	Purchased product verification
<b>7.5</b>	Production and provision for service
<b>7.5.1</b>	Production control and service provision
<b>7.5.2</b>	Product cleanliness
<b>7.5.3</b>	Installation activities
<b>7.5.4</b>	Servicing activities
<b>7.5.5</b>	Requirements particular for sterile medical devices
<b>7.5.6</b>	Processes for production validation and provision for service
<b>7.5.7</b>	Particular requirements for process validation for sterilization and for sterile barrier systems
<b>7.5.8</b>	Identification
<b>7.5.9</b>	Traceability
<b>7.5.10</b>	Customer property
<b>7.5.11</b>	Preservation of product

<b>7.6</b>	Monitoring control and measuring equipment
<b>8.</b>	Measurement, analysis, and improvement
<b>8.1</b>	General
<b>8.2</b>	Monitoring and measurement
<b>8.2.1</b>	Feedback
<b>8.2.2</b>	Complaint handling
<b>8.2.3</b>	Reporting to regulatory authorities
<b>8.2.4</b>	Internal audit
<b>8.2.5</b>	Monitoring and measurement of processes
<b>8.2.6</b>	Monitoring and measurement of product
<b>8.3</b>	Nonconforming product control
<b>8.3.1</b>	General
<b>8.3.1</b>	Actions response to nonconforming product detected before delivery
<b>8.3.2</b>	Actions response to nonconforming product detected after delivery
<b>8.3.3</b>	Rework
<b>8.3.4</b>	Analysis of data
<b>8.4</b>	Improvement: CAPA [15,16,17]
<b>8.5</b>	



**Fig. no. 3 : Quality Management System of Medical Devices**



## 4. Clinical Investigation of Medical Devices (ISO 14155)

The ISO 14155 International Standard, created by the ISO/TC 194 Technical Committee, focused on ensuring the safety and effectiveness of medical devices through clinical investigations involving human subjects. This standard provided guidelines for planning, conducting, documenting, and reporting these investigations. It consisted of two parts: ISO 14155-1 detailed procedures for the actual conduct, while ISO 14155-2 outlined prerequisites for preparing Clinical Investigation Plans (CIPs). ISO 14155 emphasized the importance of biological tests to protect human subjects and ensured that clinical investigations were carried out with scientific integrity. It helped various stakeholders, including sponsors, monitors, investigators, ethics committees, and regulatory authorities, in supervising compliance with the standard. The requirements covered planning considerations such as replicating clinical use, assessing potential risks, and organizing, monitoring, and documenting the clinical investigation of the medical device.

**Clinical Investigation:** A clinical investigation was like a special study to check if a certain device is safe and works well in people. Before starting this study, a few important things had to be in place. First, there needed to be a written plan for the study that was signed by the people in charge. Second, the ethics committee, which was a group that looked out for the well-being of the people in the study, had to give their approval. Lastly, the authorities in charge of regulations also had to give the green light. These steps ensured that the study was well-planned, ethical, and followed the rules to make sure the device was safe and effective for use in humans.

**Informed Consent:** When people decided to join a clinical study, it was very important to make sure

they fully understood and agreed. In the ISO 14155-1 standard, it said that a special process, called "obtaining informed consent," must happen. This meant that everyone who wanted to be part of the study had to give their agreement in writing. No one should have felt pressured or pushed to join. The document explaining the study, called the consent form, should have been easy to understand for the person or their legal representative. They should have had enough time to think about whether they wanted to join or not. The person or their legal representative, along with the person leading the study, all needed to sign and date this agreement. This was really important because it made sure everyone knew what was happening and agreed before the study began.

**Documentation:** Before a clinical study began, certain important documents needed to be ready. One of these was the clinical investigator's brochure, which had information about the medical device being studied. It included a summary of existing information, how the study was planned, and why the device was being used in this way. The ISO 14155-2 standard gave guidelines on what details should be in this brochure. Other documents like the plan for the study, forms for recording information, and more should also have been prepared ahead of time. Having these documents ready helped everyone involved in the study understand what was going on and why the study was being done in a certain way.

**Sponsor:** The sponsor of a clinical study had an important job. They needed to plan and tell everyone involved in the study what they should do. This included the investigator (the person leading the study), the sponsor themselves, and the monitor (someone who checked everything was going as planned). The sponsor had to make sure that everyone followed the rules laid out in ISO 14155, the plan for the study, and any





changes made to it. They also needed to show, through a clear system, that everyone was doing what they were supposed to do, following the plan and the rules from health authorities. This helped make sure the study was done the right way and followed all the necessary guidelines.

**Monitor:** The monitor played a key role in making sure the clinical study followed the plan. They checked that everything happened as it should, and if there were any changes from the plan, they discussed and recorded them with the person leading the study. At the same time, they let the sponsor know about these changes. The monitor also made sure the device was being used the way it was planned in the study, and if any adjustments were needed for the device or how it was being used, they informed the sponsor. This helped keep everything in line with the plan and ensured that any changes were documented and communicated properly.

**Clinical Investigator:** The clinical investigator was a doctor who was qualified and licensed to practice medicine. They needed to have good experience in the field and be trained in using the specific medical device being studied. The investigator had to know the background and details of the methods to be used in the study. Importantly, they should have been skilled in getting informed consent from people participating in the study. Like the sponsor and the monitor, the clinical investigator had many responsibilities to make sure the study ran smoothly every day and kept the people in the study safe. They played a crucial role in following the plan, using the device correctly, and ensuring everyone understood and agreed to be part of the study.

**Final report:** When a clinical study was finished, even if it ended earlier than planned, a final report had to be written. This report was like a summary and needed to be in writing. The sponsor, the main investigator, and other important people from

each study centre signed it. If anyone asked, this document had to be available for all the doctors involved and the ethics committee. The report had to have details about the device used, how the study was done, any changes from the plan, and a careful look at the study's goals. It also included data from all the study centres and the people who joined the study. This final report helped everyone understand what happened in the study and what was learned [18].

**Clinical Investigation Plan (CIP):** The sponsor and the clinical investigator worked together to create a document called the Clinical Investigation Plan (CIP). This plan was made to make sure the study's results were good and could be trusted. They followed the rules for doing studies, and the plan had organized information. The CIP mentioned other important papers like the Clinical Investigator's Brochure and the Sponsor's Standard Operating Procedures. If someone asked, these papers had to be shared. Sometimes, the sponsor could decide that a certain rule didn't apply, but they needed to explain why for each time they didn't follow a rule. This way, the plan helped make sure the study was done well and followed all the right steps.

## **Clearly outlining the details and features of the medical device under investigation.**

The Clinical Investigation Plan (CIP) was required to incorporate or refer to a concise description of the device being examined and its intended use. This encompassed several crucial details:

**Device Details:** When preparing a CIP plan, it was essential to include specifics such as the device's maker, model or type number, software version, and any accessories it came with. If this information wasn't available upfront, measures had to be set up to track and identify the device before and after the study, ensuring a thorough and organized cleaning process.



**Intended Use:** It was crucial to incorporate the reason the device was made, according to the manufacturer's specifications. This involved mentioning any limitations on the device's use, understanding its implications in real-life medical situations, and identifying the target demographic for the device.

**Device Characterization:** The information was required to cover all parts of the device that came into contact with tissues or body fluids. This included an explanation of any substances involved, such as medicines, human or animal tissues, or other active elements related to the device.

**Installation and Usage Instructions:** The CIP had to provide clear instructions on how to set up and use the device, including any stipulations for storing and handling it. Details about usage, reuse protocols, safety checks, and post-use precautions were also outlined.

**Training Requirements:** The CIP needed to outline the necessary training and experience required to use the device being studied effectively.

**Medical or Surgical Procedures:** The CIP contained a statement that explained any medical or surgical procedures connected to using the device, offering a comprehensive overview of the clinical context [19].

## 5. Post-Approval Changes in Medical Devices

Continuous innovation was a key aspect of the development process for medical devices. Occasionally, enhancements were made to these devices post-approval from the regulatory authority to boost their performance, quality, safety, and efficacy. These modifications were referred to as Post-Approval Changes in Medical Devices [20]. Post-approval changes referred to modifications implemented by manufacturers to a product after it had been

approved and before it was marketed. These specific alterations, which a company might wish to incorporate during the product's lifecycle, were carefully executed. The systematic approach facilitated a swift and efficient implementation of these changes, ensuring compliance with the CDSCO guidelines for post-approval modifications. There were numerous reasons why changes might be made to medical devices after they received original regulatory approval. If there were any alterations in the constitution of the foreign manufacturer or the authorized representative, the Indian authorized agent was required to inform the Central Licensing Authority (CLA) within a period of forty-five days. The CDSCO, under the D&C Act 1940 and Rules 1945, categorized these changes into two types [21]. There were two types of post-approval changes in medical devices — major changes and minor changes.

**A. Major Changes** – Modifications that carried a considerable potential to negatively impact the identity, strength, quality, or purity of a biological product, as these aspects might be related to the product's safety or effectiveness. Such significant modifications necessitated prior approval before applying for regulatory approval. The implementation of any significant changes typically took a span of 60 days. The following were considered significant changes.

**Construction Material:** The material used to build the medical device.

**Design Impact on Quality:** How the design affected the device's quality, specifications, and performance.

**Proposed Use or Indication:** The intended purpose or use of the medical device.

**Sterilization Method:** The process used to sterilize the device.



**Approved Shelf Life:** The duration for which the device was approved to remain effective and safe.

#### *Manufacturer Information:*

**Local Manufacturers:** The names or addresses of the manufacturers based in the same location as the regulatory authority are crucial information for regulatory purposes. These local manufacturers operate within the jurisdiction where the regulatory authority oversees and monitors their activities.

**Foreign Manufacturers (for Imports):** For imported medical devices, providing the names or addresses of manufacturers located outside the local jurisdiction is essential. This information helps regulatory authorities track the origin and source of the imported devices, ensuring compliance with relevant regulations and standards.

**Authorized Representative (for Imports):** In the case of imported medical devices, the name or address of the authorized representative, if applicable, is significant. The authorized representative acts as a liaison between the foreign manufacturer and the regulatory authorities in the local jurisdiction, facilitating communication and regulatory compliance.

**Label Changes:** Any modifications to the device label, excluding minor changes like font size, type, color, and overall design.

**Manufacturing Process Impact:** Information about the manufacturing process, equipment, or testing that might have influenced the quality of the device.

**Material for Primary Packaging:** The substance used for the main packaging of the device.

**B. Minor Changes** – Changes that were made to a biological product but had a low chance of causing problems with its identity, strength,

quality, or purity. These factors were crucial for the product's safety and effectiveness, and the alterations were carefully managed to ensure minimal impact. These minor changes did not necessitate approval prior to execution for regulatory clearance; such changes were considered minor. Minor changes that didn't require prior approval could be implemented after informing the CLA. These changes became effective within a period of thirty days after they were applied. A design that maintained the quality, intended use, performance, and stability of the medical device without compromising its specifications. Modifications to the manufacturing process, equipment, or testing that did not affect the device's quality. Modifications to the specifications for the packaging that didn't involve the primary packaging material [21,22].

#### **References**

1. Sethi, R.; Popli, H.; Sethi, S. Medical Devices Regulation in United States of America, European Union and India: A Comparative Study. *Pharm. Regul. Aff.* 2017 6, 179. doi:10.4172/2167-7689.1000179.
2. World Health Organization. Medical device regulations: Global overview and guiding principles. Available at: <https://fctc.who.int/publications/i/item/9241546182> (Accessed 06 December 2023).
3. Radhadevi N, Balamuralidhara V, Pramod Kumar TM, Ravi V. Regulatory guidelines for medical devices in India: An overview. *Asian J Pharm* 2012, 6, 10-7.
4. Center for Devices and Radiological Health, U.S. Food and Drug Administration. Medical Devices. Available at: <https://www.fda.gov/medical-devices> (Accessed 06 December 2023).



5. Monika Targotra, Geeta Aggarwal, Harvinder Popli, Madhu Gupta. Regulatory Aspects of Medical Devices in India. *Int. J. Drug Deliv.* 2017, 9, 18-27.
6. World Health Organization. "Risk Based Classification of Diagnostics for WHO Prequalification." WHO Prequalification of Diagnostics Public Report, [https://portaluat.who.int/pqweb/sites/default/files/documents/140513\\_who\\_risk\\_based\\_classification\\_of\\_ivds\\_for\\_pq\\_buffet.pdf](https://portaluat.who.int/pqweb/sites/default/files/documents/140513_who_risk_based_classification_of_ivds_for_pq_buffet.pdf) (Accessed: 06 December 2023).
7. Radhadevi N, Balamuralidhara V, Pramod Kumar TM, Ravi V. Regulatory Guidelines for Medical Devices in India: An Overview. *Asian J Pharm* 2012, 6, 10-17.
8. Monika Targotra, Geeta Aggarwal, Harvinder Popli, Madhu Gupta. "Regulatory aspects of medical devices in India." *International Journal of Drug Delivery* 2017, 9, 18-27.
9. Hedler, Y. David. "Reframing Product Life Cycle for Medical Devices." In *Managing Medical Devices Within a Regulatory Framework*, 2017, pp. 3-16. [cited April 30, 2020]. <https://www.sciencedirect.com/science/article/pii/B9780128041796000010>.
10. Daugherty, Sonn. Understanding the Noninvasive Medical Device Product Life Cycle. *Pacific Research Laboratories*. 2020, January 23. <https://www.pacific-research.com/understanding-the-medical-device-product-life-cycle-prl/>.
11. Mycoscience. "Good Manufacturing Practices Regulations for Medical Products." *Mycoscience Laboratories*. September 29, 2021. <https://mycoscience.com/good-manufacturing-practices-regulations-for-medical-products/>.
12. *Understanding GMP Medical Devices - Design and Development*. n.d. Compliance Quest QHSE Solutions. Accessed December 6, 2023. <https://www.compliancequest.com/compliance-management/gmp-medical-devices>.
13. Abuhav, Itay. *ISO 13485:2016: A Complete Guide to Quality Management in the Medical Device Industry*. CRC Press, Taylor & Francis, Boca Raton, 2018.
14. Frolovs, Germans, and Germans Frolovs. "Medical Device Quality Management System (QMS)." *Simpler QMS*, November 24, 2021. <https://www.simplerqms.com/medical-device-quality-management-system/>.
15. Muchemu, D. N. Designing a World-Class Quality Management System for FDA Regulated Industries: Quality System Requirements (QSR) for cGMP; Author House: Bloomington, IN, 2008; pp 14–43. ISBN 978-1-4343-4871-5 (sc); ISBN 978-1-4343-4872-2 (hc).
16. Karthika, B.; Vijayakumar, A.R. ISO 13485: Medical Devices – Quality Management Systems, Requirements for Regulatory Purposes. In: Shanmugam, P.S.T.; Thangaraju, P.; Palani, N.; Sampath, T., Eds. *Medical Device Guidelines and Regulations Handbook*; Springer: Cham, 2022; Chapter 2, [https://doi.org/10.1007/978-3-030-91855-2\\_2](https://doi.org/10.1007/978-3-030-91855-2_2).
17. Neumar RW, Otto CW, Link MS, Kronick SL, Shuster M, Callaway CW, Kudenchuk PJ, et al. Part 8: Adult Advanced Cardiovascular Life Support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. *Circulation*. 2010;122(18\_suppl\_3):S729-S767. doi:10.1161/circulationaha.110.970988.
18. Ecker, Wolfgang; Labek, Gerold; Mittermayr, Tarquin; Raffener, Brigitte;



- Ring, Michael; Schwartz, Bernhard. Clinical Evaluation and Investigation of Medical Devices under the New EU-Regulation.
19. Lanzerath, Dirk; Kielmansegg, Sebastian; Hasford, Joerg. The Development of Medical Devices: Ethical, Legal and Methodological Impacts of the EU Medical Device Regulation; Lit: Zürich, 2020.
20. India, Regulatory Solutions. "Understanding Post-Approval Changes in Medical Devices: A Comprehensive Guide." Medium, May 17, 2023. <https://regulatorysolutionsindia.medium.com/understanding-post-approval-changes-in-medical-devices-a-comprehensive-guide-d00d480ea7e8>.
21. Gupta, Harshita. 2019. "Medical Products." June 20, 2019. *Morulaa*. <https://morulaa.com/medical-device/post-approval-changes-medical-products-major-and-minor/>.
22. CDSCO. Post Approval Changes. <https://cdsco.gov.in/opencms/opencms/en/Medical-Device-Diagnostics/post-approval-changes>